Search by outcome, PheCode, body system, or focal octant. Compare every disclosure-safe phenotype curve with the directly estimated full-cohort reference, or return to the selected one-vs-rest contrast.
Panels
168
one-vs-rest M4 models
Outcomes
21
nominally omnibus-gated
Interactive curves
152
16 disclosure-withheld
Octant-exposure Incidence PheDAS
Look up any gated phenotype–outcome panel
Search 168 one-vs-rest M4 panels across 21 nominally omnibus-gated outcomes, then compare all disclosure-safe phenotype trajectories or inspect a focal contrast.
120 of 120 panels
Incident rule-of-2 PheCodes among people free of the PheCode and its control-exclusion family at index.
How correction works
Within each focal-octant contrast, PheCode tests are corrected across 15 gated outcomes (p < 0.05/15) and system tests across 6 (p < 0.05/6), not across 168 panels.
PheCode outcomes: one-vs-rest M4 models for nominally omnibus-gated outcomes.
Outcome
Focal phenotype
Adjusted M4 HR (95% CI)
q / status
3-year CIF
Quality
Symptomatic Comorbid
1.56(1.25–1.95)
0.001Bonferroni
10.05%+4.50 pp vs pooled
No EPV <10 flag
Symptom Predominant
1.91(1.34–2.72)
0.006Bonferroni
5.36%+3.80 pp vs pooled
EPV <10
Symptomatic Comorbid
1.58(1.23–2.04)
0.003Bonferroni
10.40%+5.78 pp vs pooled
No EPV <10 flag
High All
1.53(1.18–1.98)
0.011Bonferroni
4.79%+2.26 pp vs pooled
EPV <10
High All
1.58(1.19–2.10)
0.011Bonferroni
3.84%+2.36 pp vs pooled
EPV <10
High All
1.51(1.16–1.97)
0.011Bonferroni
4.64%+2.80 pp vs pooled
EPV <10
Symptom Predominant
1.58(1.16–2.15)
0.030FDR
2.17%+1.29 pp vs pooled
EPV <10
Symptomatic Comorbid
1.47(1.13–1.91)
0.022FDR
5.44%+3.08 pp vs pooled
EPV <10
High All
1.54(1.14–2.07)
0.018FDR
5.71%+2.52 pp vs pooled
EPV <10
Symptom Predominant
1.42(1.10–1.82)
0.031FDR
7.89%+2.92 pp vs pooled
No EPV <10 flag
High All
1.38(1.09–1.74)
0.021FDR
15.37%+6.17 pp vs pooled
No EPV <10 flag
Symptom Predominant
1.60(1.13–2.28)
0.032FDR
5.34%+2.80 pp vs pooled
EPV <10
High All
1.69(1.14–2.51)
0.022FDR
4.55%+0.85 pp vs pooled
EPV <10
High All
1.42(1.08–1.88)
0.027FDR
7.28%+3.73 pp vs pooled
EPV <10
Mild All
0.70(0.54–0.91)
0.115Gated
4.35%-1.97 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.71(0.54–0.93)
0.078Gated
3.17%-2.58 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.69(0.52–0.93)
0.078Gated
1.40%-2.70 pp vs pooled
No EPV <10 flag
Hypoxemic Comorbid
0.67(0.49–0.92)
0.221Gated
1.84%-1.92 pp vs pooled
EPV <10
Hypoxemia Predominant
0.70(0.52–0.94)
0.078Gated
1.30%-2.58 pp vs pooled
EPV <10
Hypoxemia Predominant
0.74(0.57–0.96)
0.078Gated
3.75%-2.68 pp vs pooled
No EPV <10 flag
Symptomatic Comorbid
1.34(1.04–1.73)
0.078Gated
5.57%+2.10 pp vs pooled
No EPV <10 flag
Symptom Predominant
1.45(1.05–2.00)
0.070Gated
7.15%+3.82 pp vs pooled
EPV <10
Symptomatic Comorbid
1.44(1.04–1.99)
0.078Gated
6.09%+2.86 pp vs pooled
EPV <10
Hypoxemic Symptomatic
1.43(1.04–1.98)
0.435Gated
6.14%+3.83 pp vs pooled
EPV <10
Comorbidity Predominant
0.74(0.56–0.97)
0.453Gated
7.07%-3.01 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.68(0.48–0.98)
0.100Gated
0.89%-1.36 pp vs pooled
EPV <10Curve withheld
Symptomatic Comorbid
1.35(1.01–1.79)
0.090Gated
8.04%+2.98 pp vs pooled
No EPV <10 flag
Symptomatic Comorbid
1.37(1.01–1.86)
0.090Gated
8.55%+5.02 pp vs pooled
EPV <10
High All
1.32(1.01–1.72)
0.081Gated
4.41%+1.93 pp vs pooled
EPV <10
High All
1.29(1.00–1.65)
0.081Gated
6.23%+2.92 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.73(0.54–1.00)
0.100Gated
2.56%-1.48 pp vs pooled
EPV <10
Hypoxemia Predominant
0.80(0.63–1.00)
0.100Gated
5.94%-4.70 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.73(0.53–1.00)
0.100Gated
0.43%-2.05 pp vs pooled
EPV <10Curve withheld
Hypoxemic Comorbid
0.74(0.54–1.01)
0.385Gated
0.10%-1.09 pp vs pooled
EPV <10Curve withheld
Mild All
0.74(0.53–1.02)
0.358Gated
3.05%-0.86 pp vs pooled
EPV <10
Hypoxemia Predominant
0.72(0.51–1.02)
0.107Gated
1.79%-1.33 pp vs pooled
EPV <10
Symptomatic Comorbid
1.27(0.98–1.65)
0.123Gated
11.03%+1.33 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
0.63(0.38–1.03)
0.509Gated
0.73%-2.35 pp vs pooled
EPV <10Curve withheld
Symptom Predominant
1.25(0.98–1.59)
0.176Gated
5.87%-0.18 pp vs pooled
No EPV <10 flag
Hypoxemic Comorbid
0.67(0.44–1.04)
0.385Gated
1.11%-2.05 pp vs pooled
EPV <10Curve withheld
High All
1.23(0.97–1.54)
0.126Gated
8.50%+2.77 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.77(0.57–1.04)
0.128Gated
1.55%-2.88 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.79(0.60–1.03)
0.435Gated
3.94%-1.46 pp vs pooled
No EPV <10 flag
Symptomatic Comorbid
1.26(0.96–1.66)
0.155Gated
4.02%+1.39 pp vs pooled
EPV <10
Hypoxemic Symptomatic
1.29(0.95–1.73)
0.435Gated
6.80%+3.57 pp vs pooled
EPV <10
Hypoxemic Comorbid
0.72(0.48–1.07)
0.394Gated
1.99%-2.07 pp vs pooled
EPV <10
Hypoxemic Symptomatic
1.28(0.94–1.74)
0.435Gated
2.38%+1.54 pp vs pooled
EPV <10
Comorbidity Predominant
0.81(0.63–1.05)
0.538Gated
6.17%+0.15 pp vs pooled
No EPV <10 flag
Mild All
0.79(0.58–1.06)
0.358Gated
1.75%-1.22 pp vs pooled
EPV <10
Hypoxemic Symptomatic
1.17(0.94–1.45)
0.472Gated
10.13%+0.39 pp vs pooled
No EPV <10 flag
Mild All
0.81(0.60–1.09)
0.358Gated
2.06%-0.77 pp vs pooled
EPV <10
Hypoxemic Comorbid
0.71(0.44–1.14)
0.474Gated
0.55%-1.67 pp vs pooled
EPV <10Curve withheld
Comorbidity Predominant
0.82(0.61–1.10)
0.538Gated
1.78%-1.07 pp vs pooled
EPV <10
Mild All
0.82(0.60–1.11)
0.358Gated
2.37%-1.85 pp vs pooled
EPV <10
Symptomatic Comorbid
0.80(0.57–1.12)
0.240Gated
1.49%-0.36 pp vs pooled
EPV <10
Mild All
0.84(0.65–1.09)
0.358Gated
3.52%-2.09 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
0.75(0.48–1.16)
0.538Gated
1.84%-2.11 pp vs pooled
EPV <10Curve withheld
Symptomatic Comorbid
1.40(0.84–2.34)
0.240Gated
3.79%+0.99 pp vs pooled
EPV <10
Symptomatic Comorbid
1.20(0.91–1.60)
0.240Gated
3.71%+1.71 pp vs pooled
EPV <10
Symptom Predominant
0.82(0.60–1.12)
0.440Gated
1.43%-1.45 pp vs pooled
EPV <10
Mild All
0.81(0.59–1.12)
0.358Gated
0.53%-0.54 pp vs pooled
EPV <10Curve withheld
Symptomatic Comorbid
1.35(0.85–2.16)
0.240Gated
2.68%-1.13 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.85(0.65–1.10)
0.535Gated
5.13%-0.23 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
0.82(0.60–1.12)
0.538Gated
0.31%-0.81 pp vs pooled
EPV <10Curve withheld
Hypoxemic Comorbid
0.84(0.64–1.11)
0.476Gated
3.11%+0.38 pp vs pooled
EPV <10
Hypoxemia Predominant
0.82(0.59–1.13)
0.295Gated
0.50%-0.58 pp vs pooled
EPV <10Curve withheld
Mild All
0.82(0.60–1.13)
0.358Gated
1.06%-1.30 pp vs pooled
EPV <10
High All
1.19(0.90–1.57)
0.316Gated
7.34%+2.28 pp vs pooled
No EPV <10 flag
Mild All
0.81(0.58–1.14)
0.358Gated
0.44%-1.54 pp vs pooled
EPV <10Curve withheld
Hypoxemia Predominant
0.84(0.62–1.12)
0.295Gated
1.41%-1.62 pp vs pooled
EPV <10
Hypoxemic Comorbid
0.84(0.63–1.12)
0.476Gated
3.97%-1.60 pp vs pooled
No EPV <10 flag
Mild All
0.85(0.65–1.11)
0.358Gated
3.82%-1.59 pp vs pooled
No EPV <10 flag
Symptom Predominant
0.80(0.56–1.16)
0.453Gated
0.33%-1.63 pp vs pooled
EPV <10Curve withheld
Hypoxemic Comorbid
1.18(0.89–1.57)
0.476Gated
3.38%+1.84 pp vs pooled
EPV <10
Comorbidity Predominant
1.20(0.88–1.64)
0.552Gated
4.79%+1.50 pp vs pooled
EPV <10
Symptom Predominant
1.19(0.87–1.64)
0.453Gated
5.16%+1.29 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.87(0.68–1.12)
0.618Gated
4.10%-2.23 pp vs pooled
No EPV <10 flag
Symptom Predominant
0.86(0.64–1.15)
0.453Gated
2.36%-1.50 pp vs pooled
No EPV <10 flag
Hypoxemia Predominant
0.86(0.64–1.15)
0.357Gated
1.87%-0.99 pp vs pooled
EPV <10
Comorbidity Predominant
0.85(0.62–1.17)
0.555Gated
2.02%+0.25 pp vs pooled
EPV <10
Hypoxemic Comorbid
0.87(0.66–1.15)
0.551Gated
4.78%-0.49 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
1.16(0.86–1.55)
0.555Gated
6.07%+0.83 pp vs pooled
No EPV <10 flag
Mild All
0.88(0.67–1.17)
0.520Gated
3.80%+0.06 pp vs pooled
No EPV <10 flag
Hypoxemic Comorbid
0.90(0.71–1.14)
0.586Gated
11.55%+2.05 pp vs pooled
No EPV <10 flag
Hypoxemic Comorbid
0.90(0.68–1.18)
0.592Gated
2.46%+0.31 pp vs pooled
EPV <10
Symptom Predominant
1.11(0.85–1.43)
0.601Gated
5.42%+0.27 pp vs pooled
No EPV <10 flag
Symptomatic Comorbid
1.12(0.83–1.51)
0.492Gated
1.57%+0.64 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.90(0.66–1.22)
0.834Gated
3.01%-1.10 pp vs pooled
EPV <10
Comorbidity Predominant
0.90(0.67–1.21)
0.738Gated
3.72%-0.27 pp vs pooled
EPV <10
Mild All
0.89(0.62–1.26)
0.624Gated
1.88%-0.13 pp vs pooled
EPV <10
Hypoxemic Symptomatic
1.12(0.79–1.60)
0.834Gated
2.76%+0.91 pp vs pooled
EPV <10
Hypoxemic Comorbid
0.92(0.70–1.20)
0.647Gated
3.67%-0.41 pp vs pooled
EPV <10
High All
1.09(0.81–1.48)
0.704Gated
1.10%+0.10 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.93(0.70–1.22)
0.834Gated
3.11%-0.70 pp vs pooled
No EPV <10 flag
Symptom Predominant
0.92(0.67–1.25)
0.721Gated
1.71%-1.22 pp vs pooled
EPV <10
Mild All
0.91(0.65–1.28)
0.694Gated
1.93%-1.10 pp vs pooled
EPV <10
Hypoxemia Predominant
0.94(0.73–1.21)
0.651Gated
3.37%-2.18 pp vs pooled
No EPV <10 flag
Hypoxemic Symptomatic
1.08(0.81–1.43)
0.834Gated
2.69%-0.04 pp vs pooled
EPV <10
Symptomatic Comorbid
1.16(0.65–2.08)
0.617Gated
3.58%+1.68 pp vs pooled
EPV <10Curve withheld
Comorbidity Predominant
0.93(0.70–1.24)
0.738Gated
3.49%+0.78 pp vs pooled
EPV <10
Symptom Predominant
0.94(0.74–1.20)
0.721Gated
9.94%+0.10 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
1.06(0.81–1.39)
0.738Gated
3.71%-0.01 pp vs pooled
No EPV <10 flag
Hypoxemic Comorbid
0.94(0.71–1.24)
0.770Gated
2.30%-0.50 pp vs pooled
EPV <10
Comorbidity Predominant
0.94(0.70–1.26)
0.738Gated
2.69%+0.54 pp vs pooled
EPV <10
Comorbidity Predominant
0.90(0.54–1.50)
0.738Gated
0.71%-1.41 pp vs pooled
EPV <10Curve withheld
Hypoxemic Comorbid
1.04(0.83–1.30)
0.799Gated
7.10%+1.21 pp vs pooled
No EPV <10 flag
Comorbidity Predominant
1.05(0.79–1.38)
0.751Gated
6.23%+1.17 pp vs pooled
No EPV <10 flag
Hypoxemic Symptomatic
0.96(0.70–1.30)
0.955Gated
0.91%-1.48 pp vs pooled
EPV <10
Symptom Predominant
0.97(0.71–1.32)
0.889Gated
3.26%-0.22 pp vs pooled
EPV <10
Hypoxemia Predominant
0.97(0.70–1.34)
0.836Gated
1.20%-0.68 pp vs pooled
EPV <10
Mild All
0.97(0.73–1.30)
0.904Gated
3.42%-0.05 pp vs pooled
EPV <10
Hypoxemic Symptomatic
0.98(0.73–1.30)
0.955Gated
3.61%+0.16 pp vs pooled
EPV <10
Symptom Predominant
1.02(0.74–1.41)
0.903Gated
1.67%-0.59 pp vs pooled
EPV <10
High All
1.03(0.60–1.76)
0.986Gated
1.65%-0.36 pp vs pooled
EPV <10Curve withheld
Hypoxemic Symptomatic
1.01(0.73–1.41)
0.955Gated
1.13%-0.76 pp vs pooled
EPV <10
High All
1.01(0.76–1.34)
0.986Gated
5.87%+0.77 pp vs pooled
No EPV <10 flag
Hypoxemic Symptomatic
1.01(0.76–1.35)
0.955Gated
2.44%-0.41 pp vs pooled
EPV <10
Hypoxemic Comorbid
1.01(0.77–1.31)
0.969Gated
3.44%-0.35 pp vs pooled
No EPV <10 flag
Mild All
1.00(0.80–1.24)
0.970Gated
9.55%-0.28 pp vs pooled
No EPV <10 flag
High All
1.00(0.62–1.64)
0.986Gated
2.76%-0.12 pp vs pooled
EPV <10Curve withheld
PheCode 563
Constipation
All available phenotype curves; the selected High All trajectory is disclosure-withheld.
BonferroniSparse data · EPV <10PH diagnostic · not evaluated
Adjusted M4 HR1.511.16–1.97 · p 0.002 · q 0.011
Chart viewCompare every disclosure-safe focal curve with the directly estimated full cohort.
Curve: unadjusted Aalen–Johansen cumulative incidence (death competing).The gray reference is estimated directly from the complete outcome-specific at-risk cohort; it is not an average of octant curves. All curve separation is descriptive, unadjusted, and noncausal. Confidence bands are not shown because no validated variance implementation is available. Exact pooled event counts are withheld to prevent reconstruction of rare focal counts.
Loading interactive curve…
Retrieving the aggregate outcome asset.
Thin 3-year tail
Mean follow-up is 1.42 years, and only 8.7% of the pooled baseline risk set remains under observation at 3 years. Read the at-risk table before quoting a 3-year cumulative incidence.
Focal 3-year CIF
4.64%
52 events / 2,521 baseline
Pooled 3-year CIF
1.84%
149 events / 18,547 baseline
Penalizer
0.01
M4 ridge Cox
Omnibus gate
p 0.040
7-df joint Wald
Incident rule-of-2 PheCodes among people free of the PheCode and its control-exclusion family at index.
Analysis and disclosure details
All eight octants are shown for each outcome whose 7-df M4 omnibus test reached nominal p < 0.05.
BH q-values were reconstructed within the original contrast-and-model families and retained only after q <= 0.05 reproduced every stored FDR flag.
Proportional-hazards diagnostics were not computed for the octant models; ph_p is unavailable for every panel. A blank value is not evidence that the assumption was met.
Exact counts below 11 are null and displayed as Suppressed (<11), never as zero. Curve coordinates are withheld for the 16 panels whose focal event count is suppressed. Their model metadata remain searchable.
Related evidence
Compare with OSA severity and landmark CPAP adherence
The phenotype-exposure curves complement—rather than replace—the main Incidence PheDAS severity analysis.